Mammoth Biosciences raises $23 million for its CRISPR-based disease detection engine

Mammoth Biosciences,  the biotech company that grew out of a close relationship with CRISPR legend Jennifer Doudna, has raised $23 million in a sturdy Series A. Mammoth previously raised $120,000 from NFX and the company continued quietly picking up funding as it built toward its exit from stealth mode in April 2018. Its current round was led by Mayfield with participation from … Συνεχίστε να διαβάζετε Mammoth Biosciences raises $23 million for its CRISPR-based disease detection engine.

Top 10 Young Companies in the Money, January–June 2018

The last time GEN published a list of top-10 private financings of early-stage biopharmas and developers of diagnostic or therapeutic technologies back in 2016, the top company turned heads by raising a then-staggering $474 million, while the No. 10 company garnered $110 million. Two years later, the same number-one company is still on top among young companies in … Συνεχίστε να διαβάζετε Top 10 Young Companies in the Money, January–June 2018.

A Deep Dive into This Year’s Biotech IPOs

  So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period. A recent analysis indicated there were nine biotech IPOs by … Συνεχίστε να διαβάζετε A Deep Dive into This Year’s Biotech IPOs.

Six Biotechs Launch IPO Plans in Last Days of May, While Iterum Therapeutics Adjusts IPO Goals

    It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs. BioSpace put together a list of some of the most recent announcements. In the last week alone … Συνεχίστε να διαβάζετε Six Biotechs Launch IPO Plans in Last Days of May, While Iterum Therapeutics Adjusts IPO Goals.